Advertisement Pharmaceutical Business review - Page 2462 of 5289 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
September 4, 2026

Superluminal Medicines secures $60m to advance rare obesity therapy

US-based biotechnology company Superluminal Medicines has completed a $60m Series B financing round to support its research into therapies for rare genetic forms of obesity and hypothalamic obesity.

Superluminal’s MC4R agonist is being developed for rare genetic forms of obesity, including BBS and hypothalamic obesity. Credit: New Africa / Shutterstock.com.